Global Interleukin 1 (IL1) Market Size By Type (APX-002, Canakinumab), By Application (Esophageal Cancer, Fallopian Tube Cancer), By Region, And Segment Forecasts, 2023 to 2032

The Global Interleukin 1 (IL1) Market was valued at USD 1.2 billion in 2023 and is projected to reach USD 3.1 billion by 2031, growing at a CAGR of 12.6% during the forecast period from 2023 to 2031. Interleukin 1, a pivotal pro-inflammatory cytokine, plays a critical role in the pathogenesis of various autoimmune, autoinflammatory, and chronic inflammatory diseases. The increasing prevalence of such diseases—coupled with rising R&D investments in targeted biologics and immunotherapies—is fueling market growth. The expanding application of IL1 inhibitors in rare and orphan indications also presents a strong growth trajectory for the market.

Drivers:

1. Rising Prevalence of Inflammatory and Autoimmune Disorders:

Chronic diseases such as rheumatoid arthritis, systemic juvenile idiopathic arthritis, and adult-onset Still’s disease are increasingly being linked to IL1 dysregulation. This has led to heightened demand for IL1-targeted biologics.

2. Expansion of Personalized Medicine:

The growing focus on biomarker-based therapies has reinforced the role of IL1-targeted agents in precision medicine, improving treatment efficacy and outcomes in a patient-specific manner.

3. Increasing R&D and Regulatory Approvals:

A surge in clinical trials evaluating IL1 blockers, particularly for rare diseases, along with a rise in FDA and EMA approvals, is accelerating the market’s expansion.

Restraints:

1. High Treatment Costs:

The premium pricing of IL1 inhibitors like anakinra and canakinumab poses affordability challenges, particularly in low- and middle-income regions.

2. Limited Awareness in Developing Markets:

The lack of diagnosis and awareness regarding IL1-related pathologies hinders the market’s penetration in emerging economies.

Opportunity:

1. Emerging Applications in Cancer and Cardiovascular Diseases:

Research suggesting IL1’s involvement in tumorigenesis and cardiovascular inflammation opens new therapeutic avenues for IL1 inhibitors.

2. Pipeline Advancements and Biologic Innovation:

Ongoing development of next-generation IL1 antagonists and long-acting formulations offers significant commercial opportunities for pharmaceutical companies.

Market by System Type Insights:

Based on system type, the Interleukin 1 Receptor Antagonists (IL1-RA) segment dominated the market in 2023. This segment, which includes widely used drugs like anakinra, continues to lead due to its established clinical efficacy and broad application base. However, the Anti-IL1β Monoclonal Antibodies segment is expected to exhibit the fastest growth, fueled by clinical success in conditions such as cardiovascular inflammation and periodic fever syndromes.

Market by End-use Insights:

In terms of end use, the Hospitals segment held the largest market share in 2023, attributed to widespread access to biologics and comprehensive care settings. The Specialty Clinics segment is anticipated to grow significantly during the forecast period, driven by the increasing number of immunology-focused outpatient centers and rising referrals for targeted cytokine therapies.

Market by Regional Insights:

Geographically, North America emerged as the largest regional market in 2023, driven by advanced healthcare infrastructure, a high prevalence of autoimmune conditions, and favorable reimbursement policies. Europe followed closely due to robust biopharma research, while Asia-Pacific is projected to witness the fastest CAGR owing to rising healthcare investments and increased clinical trial activities in China, India, and Japan.

Competitive Scenario:

Prominent players in the Global Interleukin 1 (IL1) Market include Swedish Orphan Biovitrum AB (Sobi), Novartis AG, Regeneron Pharmaceuticals, Kiniksa Pharmaceuticals, AB2 Bio Ltd., Roche, Amgen Inc., and Horizon Therapeutics. These companies are investing heavily in expanding their biologics portfolio, acquiring orphan drug designations, and forging partnerships with academic institutions and biotech firms. For instance:

In 2024, Sobi received expanded FDA approval for Kineret (anakinra) in additional inflammatory conditions.

Novartis’ Ilaris (canakinumab) continued to gain traction in treating rare fever syndromes and was evaluated in cardiovascular trials.

Regeneron and Sanofi's Kevzara (sarilumab) showed promising results in IL1-related pathologies, beyond its IL6 focus.

Scope of Work – Global Interleukin 1 (IL1) Market

Key Market Developments:

June 2024: Kiniksa Pharmaceuticals initiated Phase III trials for its IL1α/β dual inhibitor in refractory autoinflammatory conditions.

March 2024: Novartis announced new clinical data supporting canakinumab's use in preventing cardiovascular events post-myocardial infarction.

January 2025: AB2 Bio Ltd. received EMA orphan drug status for Tadekinig alfa targeting interferonopathies.

FAQs:

1) What is the current market size of the Global Interleukin 1 (IL1) Market?

The market was valued at USD 1.2 billion in 2023.

2) What is the major growth driver of the Global Interleukin 1 (IL1) Market?

The primary growth driver is the increasing prevalence of autoimmune and inflammatory disorders, coupled with advancements in biologic therapies.

3) Which is the largest region during the forecast period in the Global Interleukin 1 (IL1) Market?

North America is expected to remain the largest regional market throughout the forecast period.

4) Which segment accounted for the largest market share in Global Interleukin 1 (IL1) Market?

The Interleukin 1 Receptor Antagonists (IL1-RA) segment led the market in 2023.

5) Who are the key market players in the Global Interleukin 1 (IL1) Market?

Key players include Sobi, Novartis, Regeneron, Kiniksa Pharmaceuticals, AB2 Bio, Roche, Amgen, and Horizon Therapeutics.